Results 161 to 170 of about 4,836 (184)

Risankizumab for the treatment of psoriasis

Expert Review of Clinical Pharmacology, 2019
Introduction: The interleukin （IL）-23 and IL-17 pathway is closely related to the pathogenesis of psoriasis. This pathway is considered to be an important target for treating psoriasis. Risankizumab can selectively inhibit IL-23p19 subunit and for the treatment of psoriasis. This article aims to review risankizumab and provides reference for clinicians.
Chuanlan, Gu, Junyi, Yang
openaire   +2 more sources

Risankizumab as Maintenance Therapy for Moderately to Severely Active Crohn's Disease: Results From the Multicentre, Randomised, Double-Blind, Placebo-Controlled, Withdrawal Phase 3 FORTIFY Maintenance Trial

Lancet, The, 2022
Edward V Loftus, Julian Panes, Remo Panaccione   +2 more
exaly  

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Clinical, Cosmetic and Investigational Dermatology, 2022
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini   +2 more
exaly  

Risankizumab-Rzaa: A New Therapeutic Option for the Treatment of Crohn’s Disease

Annals of Pharmacotherapy, 2023
David K Choi, Shubha Bhat, Hilary Sheridan   +2 more
exaly  

Risankizumab (Skyrizi)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Skyrizi be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain ...
openaire   +1 more source

Risankizumab Shows High Efficacy and Maintenance in Improvement of Response Until Week 52

Dermatologic Therapy, 2022
Simone Ribero, Niccolò Siliquini, Marco Rubatto   +2 more
exaly  

Risankizumab improves PsA

Nature Reviews Rheumatology, 2022
openaire   +2 more sources

Real World Practice Indirect Comparison Between Guselkumab and Risankizumab: Results From an Italian Retrospective Study

Dermatologic Therapy, 2022
Angelo Ruggiero, Matteo Megna, Eleonora Cinelli   +2 more
exaly  

Risankizumab Compared With Adalimumab in Patients With Moderate-to-Severe Plaque Psoriasis (IMMvent): A Randomised, Double-Blind, Active-Comparator-Controlled Phase 3 Trial

Lancet, The, 2019
Kristian Reich, Diamant Thaçi, Melinda Gooderham   +2 more
exaly  

Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results From Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials

Lancet, The, 2018
Peter Foley, Luis Puig, Howard Sofen
exaly